Human IL17A Monoclonal Antibody

What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin. Synonyma: IL17, CTLA8, IL-17, ILA17, CTLA-8, IL-17A